MARKET

CING

CING

Cingulate Inc
NASDAQ
1.090
0.000
0.00%
Opening 11:13 03/28 EDT
OPEN
1.110
PREV CLOSE
1.090
HIGH
1.115
LOW
1.080
VOLUME
23.38K
TURNOVER
0
52 WEEK HIGH
23.80
52 WEEK LOW
1.000
MARKET CAP
5.20M
P/E (TTM)
-0.0334
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CING last week (0318-0322)?
Weekly Report · 3d ago
Cingulate to Participate in Benzinga All Live Access Event
Chairman and CEO Shane Schaffer will participate in a live Benzinga All Access event on March 22, 2024. Cingulate Inc. Is a biopharmaceutical company utilizing its drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products.
Barchart · 03/19 15:45
Weekly Report: what happened at CING last week (0311-0315)?
Weekly Report · 03/18 09:54
Weekly Report: what happened at CING last week (0304-0308)?
Weekly Report · 03/11 09:53
Cingulate Inc: Statement of changes in beneficial ownership of securities
Press release · 03/07 10:03
Cingulate to Attend DCAT Week 2024 in New York City
Cingulate Inc. Will be attending DCAT Week March 18-21, 2024, in Midtown Manhattan. Cingulate is a biopharmaceutical company utilizing its proprietary Precision Timed Release™ drug delivery platform technology to build a pipeline of next-generation pharmaceutical products.
Barchart · 03/06 05:45
Weekly Report: what happened at CING last week (0226-0301)?
Weekly Report · 03/04 09:54
Weekly Report: what happened at CING last week (0219-0223)?
Weekly Report · 02/26 09:59
More
About CING
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles that improve the lives of patients suffering from a multitude of commonly diagnosed conditions. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). Its CTx-1301 and CTx-1302 drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+).

Webull offers Cingulate Inc stock information, including NASDAQ: CING real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CING stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CING stock methods without spending real money on the virtual paper trading platform.